TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Abbisko Cayman Limited ( (HK:2256) ) has shared an announcement.
Abbisko Therapeutics, a subsidiary of Abbisko Cayman Limited, presented promising long-term efficacy and safety results from its Phase III MANEUVER study of pimicotinib at the CTOS 2025 Annual Meeting. The study demonstrated significant improvements in tumor response and patient quality of life, reinforcing pimicotinib’s potential for long-term use in TGCT patients. The results highlight the drug’s robust and durable response, with a notable increase in objective response rate and quality of life improvements over time, positioning Abbisko as a key player in the TGCT treatment landscape.
The most recent analyst rating on (HK:2256) stock is a Hold with a HK$14.50 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Cayman Limited operates in the pharmaceutical industry, focusing on the development of innovative therapies. Its primary product, pimicotinib, is aimed at treating tenosynovial giant cell tumour (TGCT), a rare and aggressive tumor affecting joints and tendons.
Average Trading Volume: 4,406,469
Technical Sentiment Signal: Buy
Current Market Cap: HK$10B
Find detailed analytics on 2256 stock on TipRanks’ Stock Analysis page.